![Eric Easom](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Eric Easom
Amministratore Delegato presso
AN2 THERAPEUTICS, INC.
Patrimonio netto: 7 M $ in data 30/06/2026
Profilo
Eric Easom is the founder of AN2 Therapeutics, Inc., founded in 2017, where the title held is Chairman, President & Chief Executive Officer since 2024.
Current jobs include Director at Resilient Biotics, Inc. since 2019 and Director at Chagas Disease Foundation since 2018.
Former jobs include Senior Director-Business Development & Marketing at InteKrin Therapeutics, Inc. from 2007 to 2009, Director at Infectious Disease Research Institute from 2013 to 2014, and Vice President-Neglected Diseases at Anacor Pharmaceuticals LLC from 2009 to 2017.
Education includes undergraduate studies at the University of Louisville and an MBA from Kelley School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2026 | 1.357.825 ( 3,77% ) | 7 M $ | 30/06/2026 |
Posizioni attive di Eric Easom
| Società | Posizione | Inizio |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Amministratore Delegato | 01/11/2019 |
Chagas Disease Foundation | Direttore/Membro del Consiglio | 01/06/2018 |
Resilient Biotics, Inc.
 Resilient Biotics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops microbiome-based therapeutics | Direttore/Membro del Consiglio | 01/02/2019 |
Precedenti posizioni note di Eric Easom
| Società | Posizione | Fine |
|---|---|---|
| ANACOR PHARMACEUTICALS INC | Corporate Officer/Principal | 01/06/2017 |
Infectious Disease Research Institute
 Infectious Disease Research Institute Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products to control infectious diseases | Presidente | 01/01/2013 |
InteKrin Therapeutics, Inc.
 InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for metabolic and immune disorders | Vendite & Marketing | 01/01/2009 |
Formazione di Eric Easom
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
28
Relazioni di 1° grado
8
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 8 |
|---|---|
InteKrin Therapeutics, Inc.
InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for metabolic and immune disorders | Health Technology |
University of Louisville
 University of Louisville Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Operates as a bio pharmaceutical company | Health Technology |
Infectious Disease Research Institute
Infectious Disease Research Institute Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products to control infectious diseases | Commercial Services |
Kelley School of Business
 Kelley School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Resilient Biotics, Inc.
Resilient Biotics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops microbiome-based therapeutics | Commercial Services |
AN2 Therapeutics, Inc.
 AN2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics | Health Technology |
Chagas Disease Foundation |
